ADIL Adial Pharmaceuticals Inc

4.34
+0.1  (+2%)
Previous Close 4.24
Open 4.26
52 Week Low 1.14
52 Week High 4.775
Market Cap $88,744,997
Shares 20,448,156
Float 17,760,917
Enterprise Value $79,309,844
Volume 122,638
Av. Daily Volume 658,829
Stock charts supplied by TradingView

Upcoming Catalysts

Drug Stage Catalyst Date
AD04 (ONWARD)
Alcohol use disorder
Phase 3
Phase 3
Premium membership is required to view catalyst dates, analyst ratings, earnings dates and cash burn data. Click here to unlock and sign up to a 14-day FREE TRIAL.

Latest News

  1. CHARLOTTESVILLE, Va., Sept. 15, 2021 (GLOBE NEWSWIRE) -- Adial Pharmaceuticals, Inc. (NASDAQ:ADIL, ADILW))) ("Adial" or the "Company"), a clinical-stage biopharmaceutical company focused on developing therapies for the treatment and prevention of addiction and related disorders, today announced that William Stilley, Chief Executive Officer of Adial Pharmaceuticals, has been invited to participate in Maxim Group's virtual panel series conference: "Disruptors in the Mental Health Space," which will be taking place on Wednesday, September 22, 2021 from 9:00am-3:00pm ET.

    The conference will consist of a series of roundtable panel discussions that will include speakers from both psychedelic, and non-psychedelic, focused companies. Leading and…

    CHARLOTTESVILLE, Va., Sept. 15, 2021 (GLOBE NEWSWIRE) -- Adial Pharmaceuticals, Inc. (NASDAQ:ADIL, ADILW))) ("Adial" or the "Company"), a clinical-stage biopharmaceutical company focused on developing therapies for the treatment and prevention of addiction and related disorders, today announced that William Stilley, Chief Executive Officer of Adial Pharmaceuticals, has been invited to participate in Maxim Group's virtual panel series conference: "Disruptors in the Mental Health Space," which will be taking place on Wednesday, September 22, 2021 from 9:00am-3:00pm ET.

    The conference will consist of a series of roundtable panel discussions that will include speakers from both psychedelic, and non-psychedelic, focused companies. Leading and moderating the panel discussions will be Maxim's Biotechnology Team, led by Dr. Jason McCarthy.

    Mr. Stilley has accepted an invitation as a speaker on the panel addressing addiction, which will begin at 9:00am ET. Registered attendees can view the panel via the conference platform; individual and institutional investors can sign up to register for the conference here.

    For more information about the conference, please contact Maxim at jthompson@maximgrp.com.

    About Adial Pharmaceuticals, Inc.

    Adial Pharmaceuticals is a clinical-stage biopharmaceutical company focused on the development of treatments for addictions. The Company's lead investigational new drug product, AD04, is a genetically targeted, serotonin-3 receptor antagonist, therapeutic agent for the treatment of Alcohol Use Disorder (AUD) and is currently being investigated in the Company's landmark ONWARD™ pivotal Phase 3 clinical trial for the potential treatment of AUD in subjects with certain target genotypes, which are to be identified using the Company's proprietary companion diagnostic genetic test. A Phase 2b clinical trial of AD04 for the treatment of AUD showed promising results in reducing frequency of drinking, quantity of drinking and heavy drinking (all with statistical significance), and no overt safety concerns (there were no statistically significant serious adverse events reported). AD04 is also believed to have the potential to treat other addictive disorders such as Opioid Use Disorder, gambling, and obesity. The Company is also developing adenosine analogs for the treatment of pain and other disorders. Additional information is available at www.adialpharma.com.

    Contact:

    Crescendo Communications, LLC                        

    David Waldman / Natalya Rudman                        

    Tel: 212-671-1021                                

    Email: adil@crescendo-ir.com 



    Primary Logo

    View Full Article Hide Full Article
  2. HERNDON, Va., Sept. 13, 2021 (GLOBE NEWSWIRE) -- Sysorex (OTCQB:SYSX) ("Sysorex" or the "Company"), the preeminent, U.S.-based, publicly traded Ethereum mining and technologies company, today announced that it has elected William B. Stilley, III to the Company's Board of Directors and as Chair of the Board's Audit Committee. The Company also expanded the size of its Board to five directors and established its Audit Committee.

    Mr. Stilley is the Chief Executive Officer of Adial Pharmaceuticals, Inc. (NASDAQ:ADIL), a biopharmaceutical company focused on developing therapies for the treatment and prevention of addiction and related disorders. Prior to joining Adial, he was the Vice President, Business Development & Strategic Projects at Clinical…

    HERNDON, Va., Sept. 13, 2021 (GLOBE NEWSWIRE) -- Sysorex (OTCQB:SYSX) ("Sysorex" or the "Company"), the preeminent, U.S.-based, publicly traded Ethereum mining and technologies company, today announced that it has elected William B. Stilley, III to the Company's Board of Directors and as Chair of the Board's Audit Committee. The Company also expanded the size of its Board to five directors and established its Audit Committee.

    Mr. Stilley is the Chief Executive Officer of Adial Pharmaceuticals, Inc. (NASDAQ:ADIL), a biopharmaceutical company focused on developing therapies for the treatment and prevention of addiction and related disorders. Prior to joining Adial, he was the Vice President, Business Development & Strategic Projects at Clinical Data, Inc., where Mr. Stilley was instrumental in the closing of mergers and acquisitions and licensing transactions, and was involved in management of the company's Phase 3 clinical trials, overseeing manufacturing, and sourcing drug product. Mr. Stilley also served as the Chief Operating Officer and Chief Financial Officer of Adenosine Therapeutics LLC, where he ran the internal operations of the company including research and development, and all financing activity, until its sale to Clinical Data.

    Prior to his corporate career, Mr. Stilley was Captain in the U.S. Marine Corps. Mr. Stilley earned an MBA with honors from the Darden School of Business and a B.S. in Commerce/Marketing from the McIntire School of Commerce, University of Virginia. He has guest lectured at the Darden School of Business and serves on the board of Avalon Globocare Corp. (NASDAQ:AVCO) and the Virginia BIO board of advisors.

    Wayne Wasserberg, Chief Executive Officer of Sysorex, commented, "We are very excited to welcome Bill to our Board. He brings extensive financial experience and is well-suited to his new roles as Director and Chair of Sysorex's Audit Committee. As we prepare to list our securities on a more senior market, Bill's experience as the CEO of a Nasdaq-listed company will be valuable. Bill is also exploring innovative use cases for blockchain technology at Adial and we hope to be in a position to assist with these endeavors. We believe the expansion of our Board and this appointment reinforce our commitment to the highest levels of corporate governance."

    Mr. Stilley stated, "I look forward to providing my experience to help Sysorex execute on its ambitious growth strategy. Sysorex has already established itself as a leader in Ethereum mining and technology for government services markets, and the Company is well positioned to leverage these capabilities and capitalize on emerging opportunities driven by the transition to Ethereum 2.0, as governments and corporations migrate to Ethereum and other blockchains. I also look forward to supporting a number of exciting initiatives underway that will help leverage Sysorex's robust technology into new markets such as healthcare, as we work together to build shareholder value."

    ABOUT SYSOREX, INC.

    Sysorex, Inc. ("Company") is a data center owner and operator and is the preeminent U.S.-based, publicly traded Ethereum mining and Ethereum Blockchain technologies company. Following the Company's merger with TTM Digital Assets & Technologies, Inc. ("TTM"), the Company shifted its primary business focus to the mining of Ether (ETH) and opportunities related to the Ethereum Blockchain. The Company currently owns and operates approximately 10,000 NVIDIA GPUs generating approximately 500 Gigahash of computing power, which GPUs include thousands of Cryptocurrency Mining Processors ("CMPs"). These GPUs are currently online and securing the Ethereum Blockchain and generating ETH around the clock with industry leading efficiency, and this ETH is currently being retained by Sysorex as it grows its balance sheet. In addition to the mining of ETH, the Company continues to operate its wholly owned subsidiary, Sysorex Government Services, Inc. ("SGS"), a business that provides information technology products, solutions and services to federal, state, and local government, including system integrators. The Company is also advancing strategies to leverage decentralized finance ("De-Fi") and Non-Fungible Token ("NFT") opportunities powered by the Ethereum Blockchain.

    Safe Harbor Statement

    All statements in this release that are not based on historical fact are "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995 and the provisions of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. While management has based any forward-looking statements included in this release on its current expectations, the information on which such expectations were based may change. These forward-looking statements rely on a number of assumptions concerning future events and are subject to a number of risks, uncertainties and other factors, many of which are outside of the control of Sysorex, Inc. and its subsidiaries, which could cause actual results to materially differ from such statements. Such risks, uncertainties, and other factors include, but are not limited to, the fluctuation of economic conditions, the impact of COVID-19 on Sysorex's results of operations, Sysorex's ability to integrate the products and business from recent acquisitions into its existing business, the performance of management and employees, the regulatory landscape as it relates to privacy regulations and their applicability to Sysorex's technology. Other factors that are detailed in Sysorex's periodic and current reports available for review at sec.gov. Furthermore, Sysorex operates in a highly competitive and rapidly changing environment where new and unanticipated risks may arise. Accordingly, investors should not place any reliance on forward-looking statements as a prediction of actual results. Sysorex disclaims any intention to, and undertakes no obligation to, update or revise forward-looking statements.

    Investor Relations

    Crescendo Communications, LLC

    David Waldman/Natalya Rudman

    Tel: (212) 671-1020

    Email: SYSX@crescendo-ir.com

    Company – info@ttmdigitalassets.com

    Investor Relations – ir@ttmdigitalassets.com

    Jimmy Caplan, Market Makers

    Public Relations – pr@ttmdigitalassets.com

    Rick Eisenberg, Eisenberg Communications



    Primary Logo

    View Full Article Hide Full Article
  3. CHARLOTTESVILLE, Va., Sept. 07, 2021 (GLOBE NEWSWIRE) -- Adial Pharmaceuticals, Inc. (NASDAQ:ADIL, ADILW))) ("Adial" or the "Company"), a clinical-stage biopharmaceutical company focused on developing therapies for the treatment and prevention of addiction and related disorders, today announced that William Stilley, Chief Executive Officer of Adial Pharmaceuticals, will be presenting at the H.C. Wainwright 23rd Annual Global Investment Conference being held virtually between September 13-15, 2021.

    Adial Pharmaceutical's presentation will be available on-demand to registered attendees via the conference platform beginning Monday, September 13, 2021 at 7:00 AM Eastern Time.

    The webcast can be accessed here and on the investor relations section…

    CHARLOTTESVILLE, Va., Sept. 07, 2021 (GLOBE NEWSWIRE) -- Adial Pharmaceuticals, Inc. (NASDAQ:ADIL, ADILW))) ("Adial" or the "Company"), a clinical-stage biopharmaceutical company focused on developing therapies for the treatment and prevention of addiction and related disorders, today announced that William Stilley, Chief Executive Officer of Adial Pharmaceuticals, will be presenting at the H.C. Wainwright 23rd Annual Global Investment Conference being held virtually between September 13-15, 2021.

    Adial Pharmaceutical's presentation will be available on-demand to registered attendees via the conference platform beginning Monday, September 13, 2021 at 7:00 AM Eastern Time.

    The webcast can be accessed here and on the investor relations section of Adial Pharmaceutical's website at https://ir.adialpharma.com/. Management will also be participating in one-on-one meetings with qualified members of the investor community throughout the conference.

    About Adial Pharmaceuticals, Inc.

    Adial Pharmaceuticals is a clinical-stage biopharmaceutical company focused on the development of treatments for addictions. The Company's lead investigational new drug product, AD04, is a genetically targeted, serotonin-3 receptor antagonist, therapeutic agent for the treatment of Alcohol Use Disorder (AUD) and is currently being investigated in the Company's landmark ONWARD™ pivotal Phase 3 clinical trial for the potential treatment of AUD in subjects with certain target genotypes, which are to be identified using the Company's proprietary companion diagnostic genetic test. A Phase 2b clinical trial of AD04 for the treatment of AUD showed promising results in reducing frequency of drinking, quantity of drinking and heavy drinking (all with statistical significance), and no overt safety concerns (there were no statistically significant serious adverse events reported). AD04 is also believed to have the potential to treat other addictive disorders such as Opioid Use Disorder, gambling, and obesity. The Company is also developing adenosine analogs for the treatment of pain and other disorders. Additional information is available at www.adialpharma.com.

    Contact:

    Crescendo Communications, LLC          

    David Waldman / Natalya Rudman

    Tel: 212-671-1021

    Email: adil@crescendo-ir.com



    Primary Logo

    View Full Article Hide Full Article
  4. CHARLOTTESVILLE, Va., Aug. 31, 2021 (GLOBE NEWSWIRE) -- Adial Pharmaceuticals, Inc. (NASDAQ:ADIL, ADILW))) ("Adial" or the "Company"), a clinical-stage biopharmaceutical company focused on developing therapies for the treatment and prevention of addiction and related disorders, announces it has successfully enrolled 302 patients across 25 clinical sites and has now closed enrollment for its ONWARD™ Phase 3 trial evaluating AD04 as a therapeutic agent for the treatment of Alcohol Use Disorder (AUD) in persons with certain target genotypes related to the serotonin transporter and receptor genes.

    William Stilley, Adial's Chief Executive Officer, stated, "I am pleased to report we have exceeded our enrollment target of 290 subjects. Given patient…

    CHARLOTTESVILLE, Va., Aug. 31, 2021 (GLOBE NEWSWIRE) -- Adial Pharmaceuticals, Inc. (NASDAQ:ADIL, ADILW))) ("Adial" or the "Company"), a clinical-stage biopharmaceutical company focused on developing therapies for the treatment and prevention of addiction and related disorders, announces it has successfully enrolled 302 patients across 25 clinical sites and has now closed enrollment for its ONWARD™ Phase 3 trial evaluating AD04 as a therapeutic agent for the treatment of Alcohol Use Disorder (AUD) in persons with certain target genotypes related to the serotonin transporter and receptor genes.

    William Stilley, Adial's Chief Executive Officer, stated, "I am pleased to report we have exceeded our enrollment target of 290 subjects. Given patient interest and because a larger patient population to evaluate AD04 enhances the statistical power of the trial and reduces the risk of not achieving the target number of fully completed patients in the trial, we extended our enrollment period by one month and now, with twelve additional patients enrolled, enrollment of ONWARD is now closed. Our appreciation goes out to the ONWARD clinical investigators across Scandinavia and Central and Eastern Europe, including clinical sites in Sweden, Finland, Poland, Latvia, Bulgaria and Croatia. Our team is highly encouraged by the trial retention rate and safety data to date. This data preliminarily suggests a well-tolerated therapy, which may place Adial's AD04 at a significant advantage to other currently marketed AUD therapies. Importantly, we remain on target to complete patient dosing in the first quarter of 2022 and look forward to reporting our top line data as soon as practical."

    For more information regarding ONWARD, please visit the National Institute of Health's Clinical Trials website, which should be updated shortly to reflect full enrollment of the trial.

    About Adial Pharmaceuticals, Inc.

    Adial Pharmaceuticals is a clinical-stage biopharmaceutical company focused on the development of treatments for addictions. The Company's lead investigational new drug product, AD04, is a genetically targeted, serotonin-3 receptor antagonist, therapeutic agent for the treatment of Alcohol Use Disorder (AUD) and is currently being investigated in the Company's landmark pivotal ONWARD™ Phase 3 clinical trial for the potential treatment of AUD in subjects with certain target genotypes, which are identified using the Company's proprietary companion diagnostic genetic test. A Phase 2b clinical trial of AD04 for the treatment of AUD showed promising results in reducing frequency of drinking, quantity of drinking and heavy drinking (all with statistical significance), and no overt safety concerns (there were no statistically significant serious adverse events reported). AD04 is also believed to have the potential to treat other addictive disorders such as Opioid Use Disorder, gambling, and obesity. The Company is also developing adenosine analogs for the treatment of pain and other disorders. Additional information is available at www.adialpharma.com.

    About the Landmark ONWARD™ Pivotal Phase 3 Clinical Trial

    The ONWARD trial is a 24-week, multicenter, randomized, double-blind, placebo-controlled, parallel group, pivotal Phase 3 clinical study to evaluate the efficacy, safety and tolerability of AD04 in patients with Alcohol Use Disorder (AUD) and selected polymorphisms in the serotonin transporter and receptor genes. Patients are genetically screened prior to enrollment in the ONWARD trial so that only genetically positive patients are enrolled. The primary endpoint for analysis of efficacy is the change from baseline in the monthly number of heavy drinking days during the last 8 weeks of the 24-week treatment period. ONWARD is currently being conducted in 25 clinical sites in six countries in Scandinavia and Central and Eastern Europe (Sweden, Finland, Poland, Latvia, Bulgaria and Croatia). The Coordinating Principal Investigator is Professor Hannu E.R. Alho, Emeritus Professor of Addiction Medicine at the University of Helsinki.

    Forward Looking Statements

    This communication contains certain "forward-looking statements" within the meaning of the U.S. federal securities laws. Such statements are based upon various facts and derived utilizing numerous important assumptions and are subject to known and unknown risks, uncertainties and other factors that may cause actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by such forward-looking statements. Statements preceded by, followed by or that otherwise include the words "believes," "expects," "anticipates," "intends," "projects," "estimates," "plans" and similar expressions or future or conditional verbs such as "will," "should," "would," "may" and "could" are generally forward-looking in nature and not historical facts, although not all forward-looking statements include the foregoing. The forward-looking statements include statements regarding the expectation that the ONWARD trial will be complete in the first quarter of 2022, and the potential of AD04 to treat other addictive disorders such as opioid use disorder, gambling, and obesity. Any forward-looking statements included herein reflect our current views, and they involve certain risks and uncertainties, including, among others, our ability to complete clinical trials on time and achieve desired results and benefits as expected, our ability to obtain regulatory approvals for commercialization of product candidates or to comply with ongoing regulatory requirements, regulatory limitations relating to our ability to promote or commercialize our product candidates for specific indications, acceptance of product candidates in the marketplace and the successful development, marketing or sale of products, our ability to maintain our license agreements, the continued maintenance and growth of our patent estate, our ability to establish and maintain collaborations, our ability to obtain or maintain the capital or grants necessary to fund its research and development activities, and our ability to retain our key employees or maintain our Nasdaq listing. These risks should not be construed as exhaustive and should be read together with the other cautionary statement included in our Annual Report on Form 10-K for the year ended December 31, 2020, subsequent Quarterly Reports on Form 10-Q and current reports on Form 8-K filed with the Securities and Exchange Commission. Any forward-looking statement speaks only as of the date on which it was initially made. We undertake no obligation to publicly update or revise any forward-looking statement, whether as a result of new information, future events, changed circumstances or otherwise, unless required by law.

    Contact:

    Crescendo Communications, LLC                        

    David Waldman / Natalya Rudman                        

    Tel: 212-671-1021                                

    Email: adil@crescendo-ir.com



    Primary Logo

    View Full Article Hide Full Article
  5. On track for trial completion in the first quarter of 2022

    Adial to host business update call at 11AM Eastern today

    CHARLOTTESVILLE, Va., Aug. 20, 2021 (GLOBE NEWSWIRE) -- Adial Pharmaceuticals, Inc. (NASDAQ:ADIL, ADILW))) ("Adial" or the "Company"), a clinical-stage biopharmaceutical company focused on developing therapies for the treatment and prevention of addiction and related disorders, announces it has reached its full enrollment target of 290 subjects in the Company's ONWARD™ Phase 3 trial evaluating AD04 as a therapeutic agent for the treatment of Alcohol Use Disorder (AUD) in persons with certain target genotypes related to the serotonin transporter and receptor genes. ONWARD trial completion is expected in the first quarter of…

    On track for trial completion in the first quarter of 2022

    Adial to host business update call at 11AM Eastern today

    CHARLOTTESVILLE, Va., Aug. 20, 2021 (GLOBE NEWSWIRE) -- Adial Pharmaceuticals, Inc. (NASDAQ:ADIL, ADILW))) ("Adial" or the "Company"), a clinical-stage biopharmaceutical company focused on developing therapies for the treatment and prevention of addiction and related disorders, announces it has reached its full enrollment target of 290 subjects in the Company's ONWARD™ Phase 3 trial evaluating AD04 as a therapeutic agent for the treatment of Alcohol Use Disorder (AUD) in persons with certain target genotypes related to the serotonin transporter and receptor genes. ONWARD trial completion is expected in the first quarter of 2022.

    William Stilley, Adial's Chief Executive Officer, stated, "Meeting our enrollment target is a major achievement in our ONWARD™ Phase 3 trial. I would like to thank all of the investigators involved in the trial that helped us reach this important milestone in spite of the ongoing pandemic. Trial engagement interest among patients continues to be strong, and consistent with what was seen in previous clinical testing; approximately 33% of those patients screened tested positive for the genetics expected to indicate responsiveness to AD04. Our confidence in the market potential of AD04 is bolstered by this apparent confirmation of the percentage of the population with the target genetics. We estimate the market potential for AD04 to be in excess of $36 billion in the U.S. alone, and we are evaluating marketing and distribution channel partners in the United States and abroad."

    Mr. Stilley continued, "Due to increased demand for entry into the study near the end of our trial recruitment period, we still have additional patients that have been genetically screened as positive for enrollment in the study but have not yet been enrolled in ONWARD™. With this opportunity to rapidly enroll additional patients to increase the statistical power of the trial, and, we have determined to enroll these additional, already screened patients through the end of this month. This means total trial enrollment will exceed our enrollment goal of 290 patients."

    "We are also encouraged by the high study retention rate with more patients than expected continuing to engage in the trial following enrollment. Moreover, no serious adverse events have been reported to date that have been determined to be study drug related, and the vast majority of adverse events have been mild and also unrelated. The retention rate and safety data are supportive of a well-tolerated therapy, differentiating AD04 from other marketed AUD therapies."

    Conference Call

    Adial will host a conference call at 11:00 A.M. Eastern Time today, on Friday, August 20, 2021. The conference call will be available via telephone by dialing toll free 844-369-8770 for U.S. callers or +1 862-298-0840 for international callers. A webcast of the call may be accessed at https://www.webcaster4.com/Webcast/Page/2463/42538 or on the Company's website at https://ir.adialpharma.com/.

    An audio replay of the call will be available through September 3, 2021 and can be accessed by dialing 877-481-4010 for U.S callers or +1 919-882-2331 for international callers and by entering the access code: 42538.

    About Adial Pharmaceuticals, Inc.

    Adial Pharmaceuticals is a clinical-stage biopharmaceutical company focused on the development of treatments for addictions. The Company's lead investigational new drug product, AD04, is a genetically targeted, serotonin-3 receptor antagonist, therapeutic agent for the treatment of Alcohol Use Disorder (AUD) and is currently being investigated in the Company's landmark ONWARD™ pivotal Phase 3 clinical trial for the potential treatment of AUD in subjects with certain target genotypes, which are to be identified using the Company's proprietary companion diagnostic genetic test. A Phase 2b clinical trial of AD04 for the treatment of AUD showed promising results in reducing frequency of drinking, quantity of drinking and heavy drinking (all with statistical significance), and no overt safety concerns (there were no statistically significant serious adverse events reported). AD04 is also believed to have the potential to treat other addictive disorders such as Opioid Use Disorder, gambling, and obesity. The Company is also developing adenosine analogs for the treatment of pain and other disorders. Additional information is available at www.adialpharma.com.

    About the Landmark ONWARD™ Pivotal Phase 3 Clinical Trial

    The ONWARD trial is a 24-week, multicenter, randomized, double-blind, placebo-controlled, parallel group, Phase 3 clinical study to evaluate the efficacy, safety and tolerability of AD04 in patients with Alcohol Use Disorder (AUD) and selected polymorphisms in the serotonin transporter and receptor genes. Patients are genetically screened prior to enrollment in the ONWARD trial so that only genetically positive patients are enrolled. The primary endpoint for analysis of efficacy is the change from baseline in the monthly number of heavy drinking days during the last 8 weeks of the 24-week treatment period. ONWARD is currently being conducted in 25 clinical sites in seven countries in Scandinavia and Central and Eastern Europe (Sweden, Finland, Poland, Latvia, Estonia, Bulgaria and Croatia). The principal investigator is Professor Hannu E.R. Alho, Emeritus Professor of Addiction Medicine at the University of Helsinki.

    Forward Looking Statements

    This communication contains certain "forward-looking statements" within the meaning of the U.S. federal securities laws. Such statements are based upon various facts and derived utilizing numerous important assumptions and are subject to known and unknown risks, uncertainties and other factors that may cause actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by such forward-looking statements. Statements preceded by, followed by or that otherwise include the words "believes," "expects," "anticipates," "intends," "projects," "estimates," "plans" and similar expressions or future or conditional verbs such as "will," "should," "would," "may" and "could" are generally forward-looking in nature and not historical facts, although not all forward-looking statements include the foregoing. The forward-looking statements include statements regarding the ONWARD trial completion being expected in the first quarter of 2022, the target genetics expected to indicate responsiveness to AD04 the market potential for AD04 being in excess of $36 billion in the U.S. alone and the potential of AD04 to treat other addictive disorders such as opioid use disorder, gambling, and obesity. Any forward-looking statements included herein reflect our current views, and they involve certain risks and uncertainties, including, among others, our ability to achieve key milestones for our pre-clinical adenosine program for non-opiate pain relief, our ability to complete clinical trials on time and achieve desired results and benefits as expected, our ability to obtain regulatory approvals for commercialization of product candidates or to comply with ongoing regulatory requirements, regulatory limitations relating to our ability to promote or commercialize our product candidates for specific indications, acceptance of its product candidates in the marketplace and the successful development, marketing or sale of products, our ability to maintain our license agreements, the continued maintenance and growth of our patent estate, our ability to establish and maintain collaborations, our ability to obtain or maintain the capital or grants necessary to fund its research and development activities, and our ability to retain our key employees or maintain our Nasdaq listing. These risks should not be construed as exhaustive and should be read together with the other cautionary statement included in our Annual Report on Form 10-K for the year ended December 31, 2020, subsequent Quarterly Reports on Form 10-Q and current reports on Form 8-K filed with the Securities and Exchange Commission. Any forward-looking statement speaks only as of the date on which it was initially made. We undertake no obligation to publicly update or revise any forward-looking statement, whether as a result of new information, future events, changed circumstances or otherwise, unless required by law.

    Contact:

    Crescendo Communications, LLC

    David Waldman / Natalya Rudman

    Tel: 212-671-1021

    Email: adil@crescendo-ir.com



    Primary Logo

    View Full Article Hide Full Article
View All Adial Pharmaceuticals Inc News